Adolescent GLP-1 Prescriptions Increased 600% From 2020 To 2023

Among adolescents ages 12 to 17 years and young adults ages 18 to 25 years, the number prescribed a glucagon-like peptide-1 receptor agonist (GLP-1RA) medication increased by nearly 600% between 2020 and 2023, rising from 8,722 to 60,567. This class of medications includes dulaglutide, exenatide, liraglutide, semaglutide, and tirzepatide. The first three are approved to treat type 2 diabetes in adolescents and adults. Liraglutide and semaglutide are approved for weight management in adolescents and adults. Tirzepatide is only approved for adult use for weight management.

Prescribing was higher for females in both age groups than . . .